Newborn screening is important for the early detection of metabolic disorders, aimed at the earliest possible recognition and management of affected newborns, to prevent the morbidity, mortality, and disabilities associated with an inherited metabolic disorder. This comprehensive system includes; testing, education, follow up, diagnosis, treatment, management, and evaluation.
“Climb has been a valued partner in many developments in newborn screening and metabolic disease. Notably it played a key role in the development of expanded newborn screening and continues to collaborate in relation to research on the best ways to communicate with and support families with inherited metabolic disorders. Climb has been a real asset and friend within the metabolic community.”
Professor J R Bonham
Division of Pharmacy, Diagnostics and Genetics
Sheffield Children’s NHS Foundation Trust
Read more about the Expanded newborn blood spot screening programme here